Snord 3A: a molecular marker and modulator of prion disease progression.
Since preventive treatments for prion disease require early identification of subjects at risk, we searched for surrogate peripheral markers characterizing the asymptomatic phases of such conditions. To this effect, we subjected blood mRNA from E200K PrP CJD patients and corresponding family members to global arrays and found that the expression of Snord3A, a non-coding RNA transcript, was elevated several times in CJD patients as compared to controls, while asymptomatic carriers presented intermediate Snord3A levels. In the brains of TgMHu2ME199K mice, a mouse model mimicking for E200K CJD, Snord 3A levels were elevated in an age and disease severity dependent manner, as was the case for brains of these mice in which disease was exacerbated by copper administration. Snord3A expression was also elevated in scrapie infected mice, but not in PrP(0/0) mice, indicating that while the expression levels of this transcript may reflect diverse prion etiologies, they are not related to the loss of PrP(C)'s function. Elevation of Snord3A was consistent with the activation of ATF6, representing one of the arms of the unfolded protein response system. Indeed, SnoRNAs were associated with reduced resistance to oxidative stress, and with ER stress in general, factors playing a significant role in this and other neurodegenerative conditions. We hypothesize that in addition to its function as a disease marker, Snord3A may play an important role in the mechanism of prion disease manifestation and progression.
Department of Neurology, Hadassah Medical Center, The Agnes Ginges Center of Human Neurogenetics, Jerusalem, Israel.
Eran
E
Cohen
Dana
D
Avrahami
Kati
K
Frid
Tamar
T
Canello
Ephrat
E
Levy Lahad
Sharon
S
Zeligson
Shira
S
Perlberg
Joab
J
Chapman
Oren S
OS
Cohen
Esther
E
Kahana
Iris
I
Lavon
Ruth
R
Gabizon
D051702:Activating Transcription Factor 6; D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D003300:Copper / Q000008:administration & dosage; D018450:Disease Progression; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D051379:Mice; D018621:PrPC Proteins / Q000235:genetics / Q000378:metabolism; D017096:Prion Diseases / Q000235:genetics / Q000378:metabolism*; D011328:Prions / Q000378:metabolism; D020537:RNA, Small Nucleolar / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*; D022661:RNA, Untranslated / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism*
D051702:Activating Transcription Factor 6; C497112:Atf6 protein, mouse; D015415:Biomarkers; D018621:PrPC Proteins; D011328:Prions; D020537:RNA, Small Nucleolar; D022661:RNA, Untranslated; D003300:Copper